ChroMedX Receives US Patent on Automated Ultra-Filtration System
Toronto, Ontario--(Newsfile Corp. - April 6, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that it has received formal Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its Automated Ultra Filtration (AUF) technology patent Pat. Application No. 14/725,690, which was filed on May 29, 2015. The Company's AUF technology will allow the preparation of...
2017-04-06 4:30 PM EDT
ChroMedX Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - February 2, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company") is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement (the "Offering") by issuing 4,073,667 units ("Units") at a price of $0.15 per Unit for aggregate gross proceeds of $611,050.05. Each Unit is comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant...
2017-02-02 4:15 PM EST
ChroMedX Provides 2016 Development Summary and Reports on Recent Warrant Exercise and Expiration
Toronto, Ontario--(Newsfile Corp. - January 16, 2017) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to provide a 2016 development summary and report on development initiatives in 2017. The Company also reports on recent expiration and exercise of warrants. In 2016 the Company's core focus was the development and testing of the HemoPalm biosensor component and to commence assembly of the HemoPalm...
2017-01-16 4:15 PM EST
ChroMedX Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - December 29, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company") is pleased to announce that it has closed a non-brokered private placement (the "Offering") of 1,227,000 units ("Units") at a price of $0.15 per Unit for aggregate gross proceeds of $184,050. Each Unit is comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant entitles the holder thereof to...
2016-12-29 5:56 PM EST
ChroMedX Collaboration with Biointerface Institute Receives OCE Grant for HemoPalm Biosensor Development
Toronto, Ontario--(Newsfile Corp. - December 2, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that it's collaboration with Dr. Leyla Soleymani and the Biointerface Institute of McMaster University has received a Voucher for Innovation and Productivity I (VIP I) grant from Ontario Centres of Excellence (OCE) for continued HemoPalm biosensor development. The VIP I program helps...
2016-12-02 8:12 PM EST
ChroMedX Receives Computer Interface and CO-oximetry Modules for Prototype Assembly
Toronto, Ontario--(Newsfile Corp. - November 29, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that the Company has taken delivery of the HemoPalm computer interface and CO-oximetry modules for assembly of a handheld prototype. The modules come from the Company's development partner, analytical equipment developer Dr. Licht GmbH, of Numbrecht, Germany. ChroMedX worked closely with...
2016-11-29 4:15 PM EST
ChroMedX Corp. Commences Biosensor Testing
Toronto, Ontario--(Newsfile Corp. - November 25, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that the Company has commenced testing of its biosensor component and is receiving positive results. Testing on the biosensors commenced earlier this month at McMaster University where the Company has conducted its biosensor development initiative since early this year. Results are now...
2016-11-25 4:15 PM EST
ChroMedX Files Global Patent Protection on HemoPalm Handheld Blood Analyzer System
Toronto, Ontario--(Newsfile Corp. - November 22, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), developer of the HemoPalmTM Handheld Blood Analyzer System, is pleased to announce the filing of global patent protection on its key patent entitled "Joint Spectroscopic and Biosensor System for Point-of-Care Testing". The system includes a handheld analyzer and disposable cartridges. ChroMedX received a US patent in September of this year and has now filed for patent...
2016-11-22 4:15 PM EST
ChroMedX Corp. Appoints Ash Kaushal to Board of Directors
Toronto, Ontario--(Newsfile Corp. - November 14, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and Point-of-care Testing technologies is pleased to announce the appointment of Ash Kaushal to the Company's Board of Directors in addition to his role as President and CEO as announced July 2016. The Company's Board of Directors has been very pleased with Mr. Kaushal's leadership in recent months and is proud to announce his...
2016-11-14 7:30 AM EST
ChroMedX Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - October 24, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company") is pleased to announce that it has closed a non-brokered private placement (the "Offering") of 4,400,000 units ("Units") at a price of $0.125 per Unit for aggregate gross proceeds of $550,000. Each Unit is comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant entitles the holder thereof to...
2016-10-24 4:05 PM EDT
ChroMedX Receives US Patent on Flagship HemoPalm Analyzer Technology
Toronto, Ontario--(Newsfile Corp. - September 26, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) technologies is pleased to announce that it has received formal Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Pat. Application No. 15/144,073, which is a continuation of PCT/CA2015/050455 filed 20th May 2015. The allowed patent is published under publication...
2016-09-26 4:35 PM EDT
ChroMedX Announces Appointment of Ash Kaushal as President and CEO
Toronto, Ontario--(Newsfile Corp. - July 26, 2016) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and Point-of-care Testing (POCT) technologies is pleased to announce the appointment of Ash Kaushal as the Company's new President and CEO, effective immediately. Mr. Kaushal has over 25 years of experience in product development in the medical, defence, safety and nuclear industries. Mr. Kaushal has held Vice President and senior level...
2016-07-26 6:00 AM EDT
ChroMedX Reports on HemoPalm Development
Toronto, Ontario--(Newsfile Corp. - April 29, 2016) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and Point-of-care Testing technologies is pleased to report on the Company's HemoPalm development programme. During the first four months of 2016, ChroMedX focused on refining the HemoPalm cartridge design through machining, and developing essential components of the HemoPalm analyzer. "We have made significant progress so far in 2016...
2016-04-29 4:20 PM EDT
ChroMedX Corp. Engages Conductive Technologies Inc. for Biosensor Development Programme
Toronto, Ontario--(Newsfile Corp. - April 20, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce the engagement of Conductive Technologies Inc. (CTI) of York, Pennsylvania to assist with biosensor development on the Company's HemoPalm technology. ChroMedX has previously reported on the collaboration with Polygenesis on the development of the biosensor system and associated...
2016-04-20 4:15 PM EDT
ChroMedX Corp. Extends Expiry Date of Certain Warrants
Toronto, Ontario--(Newsfile Corp. - February 22, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2), a developer of in vitro diagnostics and point-of-care testing (POCT) announces that, in accordance with CSE policies, it intends to extend the expiry date of an aggregate of 8,572,500 previously issued warrants (the "Warrants"). The Warrants were originally issued between July 7, 2014 and September 22, 2014, with original expiry dates ranging from March 5, 2016 to July 7, 2016. As a...
2016-02-22 3:17 PM EST
ChroMedX Completes Proof-of-Concept CO-oximetry and Bilirubin Prototype Development
Toronto, Ontario--(Newsfile Corp. - December 11, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) devices is pleased to report the development of a proof-of-concept prototype of the Company's HemoPalmTM analyzer and associated cartridge for measuring CO-oximetry and bilirubin*. The prototype analyzer uses the same light source and spectrophotometer that will be used in the final HemoPalmTM...
2015-12-11 4:15 PM EST
ChroMedX Engages Hochuen International Corp. for Improved Prototype Cartridge Production
Toronto, Ontario--(Newsfile Corp. - December 8, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report that it has engaged Hochuen International Corp. to produce an enhanced version of its prototype HemoPalm cartridges. ChroMedX Corp. has entered into a development agreement with Hochuen International Corp. to produce the enhanced version of its HemoPalm cartridges by machining as...
2015-12-08 4:10 PM EST
ChroMedX Corp. Announces Closing of First Tranche of Private Placement
Toronto, Ontario--(Newsfile Corp. - October 16, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that it has completed the first tranche of its previously announced non-brokered private placement (the "Offering"), pursuant to which the Company issued and sold an aggregate of 1,750,000 units (each, a "Unit") of the Company at a price of CDN$0.20 per Unit for aggregate gross...
2015-10-16 6:40 PM EDT
ChroMedX Corp. Awarded New United States Patent on Ultra Filtration Technology
Toronto, Ontario--(Newsfile Corp. - October 14, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that the Company has been awarded a United States patent on its Ultra Filtration technology. ChroMedX was awarded US Pat. No. 9,162,186, entitled "Sample Filtration Assembly". This patent is related to manual ultrafiltration cartridges, and while related to two recently...
2015-10-14 4:09 PM EDT
ChroMedX Corp. Announces Private Placement of Units
Toronto, Ontario--(Newsfile Corp. - October 9, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that it intends to complete a non-brokered private placement (the "Offering") for gross proceeds of up to CDN$800,000 through the issuance of up to 4,000,000 units (each a "Unit") at a price of CDN$0.20 per Unit. Each Unit will be comprised of one common share of the Company (a...
2015-10-09 8:15 PM EDT